Pulmonx (LUNG) Liabilities and Shareholders Equity (2019 - 2025)

Pulmonx (LUNG) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $129.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Liabilities and Shareholders Equity fell 20.61% year-over-year to $129.3 million in Q4 2025; TTM through Dec 2025 was $565.5 million, a 15.28% decrease from a year earlier, with the FY2025 full-year figure at $129.3 million, down 20.61% from the prior year.
• Liabilities and Shareholders Equity was $129.3 million for Q4 2025 at Pulmonx, down from $138.3 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $255.3 million in Q1 2021 and troughed at $129.3 million in Q4 2025.
• A 5-year average of $190.4 million and a median of $189.1 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity soared 246.44% in 2021 and decreased 20.61% in 2025, its largest moves.
• Over 5 years, Liabilities and Shareholders Equity stood at $235.2 million in 2021, then slipped by 17.65% to $193.7 million in 2022, then fell by 8.21% to $177.8 million in 2023, then decreased by 8.4% to $162.8 million in 2024, then declined by 20.61% to $129.3 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $129.3 million (Q4 2025), $138.3 million (Q3 2025), and $147.2 million (Q2 2025), per Business Quant data.